Tag: Synchron

11 articles

Policy & Regulation

FDA workshop uses ALS brain implants as its case study for small device trials

At a September FDA workshop on rare disease statistics, the FDA's background paper on device studies used brain-computer interfaces for ALS as its case example for testing devices in small populations. An FDA official said more uncertainty before approval may be acceptable when it is paired with post-market data collection, Synchron's Adam Fry said he does not think implant trials can be blinded effectively or ethically, and Paradromics said it is using its Connect-One study to design the measures for its pivotal trial.

Nov 17

Industry News

Precision Neuroscience partners with ALS charity Team Gleason

Precision Neuroscience and Team Gleason, the ALS charity founded by former New Orleans Saints player Steve Gleason, announced a partnership on 13 November 2026. People living with ALS, their families and caregivers will get a structured way to give feedback on Precision's brain-computer interface while it is in development, and the two will run joint education on its Layer 7 system for patients and clinicians, starting at the American Speech-Language-Hearing Association convention. Team Gleason first partnered with Synchron in 2022.

Nov 15

Market Moves

Synchron's long road to reaching the brain through a blood vessel

Synchron began with a cold email from Tom Oxley to DARPA in 2011 and a US$1 million offer to build a brain implant that travels through the veins. Fifteen years on it has put its first-generation Stentrode into ten people in Melbourne and the United States, raised US$345 million, connected its implant to Apple devices, Amazon's Alexa and OpenAI's models, and started trials of a fully wireless second-generation device. Enrolment in its US and Australian trials is paused while Synchron upgrades the hardware, and the company says it will restart once that work is finished.

Nov 13

Industry News

Synchron pauses enrolment in its Stentrode trials over a problem with the implant's lead

Synchron has paused enrolment in trials of its updated, fully wireless Stentrode after a performance problem with the lead, the cable that carries signals from the Stentrode to the implanted electronics. The company says it chose to pause on its own and that no device-related safety issues have been found, and it is upgrading the whole system before restarting. WIRED reported that Synchron is also cutting jobs and scaling back in New York while building a San Diego team for a new device. Separately, the registry entry for its Canadian study lists it as terminated in September for insufficient recruitment.

Nov 13

Industry News

Neuralink cuts some implant users' calibration from 10 minutes a day to 10 minutes a week

Neuralink said on 1 October 2026 that participants in its clinical trial have streamed more than 50,000 hours of unlabelled brain recordings during everyday use of its implant, and that it has used participants' own recordings to pretrain participant-specific models that steady the software turning brain signals into cursor movement. Calibration had averaged 55 minutes a week across participants, typically 10 minutes at the start of each day; some participants now calibrate for 10 minutes a week. Six participants set personal bests on Neuralink's cursor test, and one reached 11.32 bits per second, which the company calls a record for a brain-computer interface. Every live result came from a model trained on a single participant's data, and models pooled across participants have not yet performed better. Neuralink's stated next goals are calibrating once, never calibrating, and a shared 'API for the motor cortex' for developers.

Oct 3

Industry News

Apple buys the assets of neural-sensor startup Sonera Magnetics

Apple's purchase of certain assets of Berkeley-based magnetic-sensor startup Sonera Magnetics, with job offers to some of its employees, notified to the European Commission on 8 May 2026 and disclosed publicly on 8 September 2026 via its Digital Markets Act acquisitions database, is the company's first move from hosting third-party brain-computer interface signals to owning proprietary neural-sensor IP. Sonera builds solid-state acoustically-driven ferromagnetic resonance (ADFMR) magnetometers, a room-temperature alternative to SQUID-based magnetoencephalography (MEG). The company raised US$11 million in seed financing in September 2023 from a lead-heavy syndicate including Founders Fund, Benchmark, Amplify Partners, IVP, Craft Ventures, and 8VC. Deal terms were not disclosed. Sonera's website has been taken offline. Apple's prior BCI-adjacent moves were the AirPods ear-canal biosignal patent (filed January 2023), the BCI HID accessibility protocol for iOS 26, iPadOS 26 and visionOS 26 launched with Synchron on 13 May 2025, and hosting of Cognixion's non-invasive EEG clinical trial on Vision Pro from October 2025. Owning Sonera's magnetic-sensor IP puts Apple directly against Meta's Neural Band (surface EMG) and the non-surgical BCI operator field (Merge Labs ultrasound, Subsense nanoparticle, Neurable EEG earbuds).

Sep 9

Market Moves

Bill Ackman commits $400 million to a new brain research institute after his daughter's brain haemorrhage

Hedge fund manager Bill Ackman and designer Neri Oxman announced the Ackman Oxman Institute (AOI) on 19-20 August 2026, seeded with $400 million in Pershing Square Inc. stock and a stated further commitment of similar or greater size in a form other than Pershing Square stock. The institute focuses on brain research, rehabilitation, longevity, and human optimization, with Mount Sinai as an important clinical partner. Ackman cited Neuralink, Precision Neuroscience, Synchron, Science Corp and Nudge as examples of the BCI field the institute will engage with, without claiming direct equity in any of them.

Aug 22